Gillian McGovern, Associate Editor

According to the investigators, BBO-8520 represents a first-in-class approach to treating patients with previously treated KRASG12C-mutated metastatic non-small cell lung cancer (NSCLC).

If approved, nipocalimab can treat antibody positive individuals with generalized myasthenia gravis.

Virtual appointments were also an accessible alternative to in-person visits for patients who face obstacles accessing asthma care.

The pharmacist’s role includes educating and making recommendations, collaborating with health care professionals, and observing early signs of cognitive impairment in patients during interactions.

The observational study shows a positive correlation between smoking and chronic kidney disease (CKD) whereas the analyses imply smoking-related covariates may be a factor.

The designation follows positive phase 2a trial results (NCT05104853) presented at the 2024 AASLD The Liver Meeting.

In a phase 2 trial (NCT05400226), abenacianine helps surgeons visualize tumors in lung during surgery and is safe and well-tolerated in patients.

The investigators note that the test can allow health care professionals to more accurately prescribe medication or treatments.

The tablets are indicated for treatment of adults with chronic idiopathic constipation, with further research needed to assess efficacy and safety in children.

These inequalities, which can include socioeconomic disparities, show neurological changes associated with aging and dementia.

Early diagnosis of chronic kidney disease (CKD) can help optimize treatment and manage the disease to prevent further decline.

Investigators did not report serious adverse events or deaths related to depemokimab in either of the 2 phase 3a clinical trials.

Female adolescents were at an increased risk of experiencing depression and anxiety symptoms compared with males.

Of these chemicals, 414 were found to be commonly used in plastics and consumer goods, such as food packaging and personal care products.

The approval comes after clinical trial results in which vanzacaftor/tezacaftor/deutivacaftor (Alyftrek; Vertex Pharmaceuticals) demonstrated superiority compared with elexacaftor/tezacaftor/ivacaftor and ivacaftor (Trikafta; Vertex Pharmaceuticals).

The approval follows positive results from the V005 (NCT03005418) clinical trial.

The findings show a need for researchers and health care professionals to consider model designs to minimize disparities when diagnosing perinatal mood and anxiety disorders (PMADs).

The indication is for patients with locally advanced or metastatic disease who have not previously received treatment with an ALK-inhibitor.

These findings indicate that asthma and allergic rhinitis may be commonly linked, emphasizing the need to identify underlying causes.

If approved, cyclobenzaprine hydrochloride (HCl) will be the first member of a new class of analgesic drugs for fibromyalgia.

The investigators also find that age of initiation and frequent use were not associated with a greater age-related cognitive decline.

The authors note that routine screening in patients with primary ciliary dyskinesia to help identify undiagnosed asthma.

The indication is for adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or radiation.

Despite the overall decline in medication non-adherence, adult patients with asthma are continuing to report taking less or skipping doses and refilling prescriptions later to save money.

The treatments are currently undergoing evaluation in the SOLSTICE trial (NCT05461170).

Improvements were observed regardless of whether patients initiated ruxolitinib in the second or third line of treatment.

The pumps can now be used to treat pediatric patients who have symptomatic acute decompensated heart failure and cardiogenic shock.

Compared with placebo, patients with relapsed/refractory (R/R) follicular lymphoma (FL) who were treated with tafasitamab showed a median progression-free survival (PFS) of 22.4 months.

Currently, the treatment is undergoing evaluation in a phase 2a trial.

This update follows May 2021 guidelines which recommended patients with primary biliary cholangitis (PBC) with advanced cirrhosis discontinue obeticholic acid.